PHATHOM PHARMACEUTICALS, INC. Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense
PHATHOM PHARMACEUTICALS, INC. (PHAT) reported Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Expense Statement › Interest Expense
us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense · last filed 2026-02-26
- PHATHOM PHARMACEUTICALS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2025 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2024 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2023 was $0.00.
- PHATHOM PHARMACEUTICALS, INC. unrecognized tax benefits, income tax penalties and interest expense for fiscal 2022 was $0.00.
| Period end | Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense 12 month |
|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2024-12-31 | $0.00 10-K · filed 2026-02-26 |
| 2023-12-31 | $0.00 10-K · filed 2025-03-06 |
| 2022-12-31 | $0.00 10-K/A · filed 2024-06-14 |
| 2021-12-31 | $0.00 10-K · filed 2022-03-01 |
| 2020-12-31 | $0.00 10-K · filed 2021-03-30 |
| 2019-12-31 | $0.00 10-K · filed 2020-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| CRESCENT BIOPHARMA, INC. (CBIO) | United States | $0.529B | -5.20 |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 |